BridgeMD
New treatment option for Psoriasis
Official title Evaluation of IL 12B Genetic Polymorphism (rs3213094)
ClinicalTrials.gov ID: NCT07128472
What this study is testing
What is Humira?
Humira is an investigational medicine, being studied as a potential treatment for psoriasis.
Also referred to as IL 12B genetic polymorphism (rs3213094).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Psoriasis is a skin disorder that is chronic proliferative and inflammatory in nature. Extensor surfaces, scalp, and lumbosacral area are covered in erythematous plaques with silvery scales.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70. Healthy volunteers may be eligible.
You may be able to join if
- \- Patients having psoriasis diagnosed clinically for at least 6 months and who have a severity grade of severe, defined as a Psoriasis Area and...
You likely can't join if
- Patients with other autoimmune or inflammatory conditions (e.g., rheumatoid arthritis, lupus).
- Pregnancy and lactation.
- Patients currently undergoing any treatment other than Humira.
- Patients with known genetic disorders affect immune system function.
- Patients were undergoing any treatment other than Humira in the last 6 months.
- Patients with active infections, including tuberculosis or chronic viral infections (e.g., hepatitis B or C, HIV).
See the full eligibility criteria
- \- Patients having psoriasis diagnosed clinically for at least 6 months and who have a severity grade of severe, defined as a Psoriasis Area and Severity Index (PASI) score greater than 10, and involvement of greater...
- Patients with other autoimmune or inflammatory conditions (e.g., rheumatoid arthritis, lupus).
- Pregnancy and lactation.
- Patients currently undergoing any treatment other than Humira.
- Patients with known genetic disorders affect immune system function.
- Patients were undergoing any treatment other than Humira in the last 6 months.
- Patients with active infections, including tuberculosis or chronic viral infections (e.g., hepatitis B or C, HIV).
- Patients with contraindication to Humira.
- Renal \&Vascular diseases
The study team makes the final eligibility decision.
Where it's taking place
- Qina, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Qina, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.